Provided by Tiger Fintech (Singapore) Pte. Ltd.

Fate Therapeutics

0.9415
-0.0020-0.21%
Post-market: 0.94480.0033+0.35%19:49 EDT
Volume:1.42M
Turnover:1.33M
Market Cap:107.89M
PE:-0.57
High:0.9695
Open:0.9695
Low:0.9102
Close:0.9435
Loading ...

Company Profile

Company Name:
Fate Therapeutics
Exchange:
NASDAQ
Establishment Date:
2007
Employees:
181
Office Location:
12278 Scripps Summit Drive,San Diego,California,United States
Zip Code:
92131
Fax:
- -
Introduction:
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Directors

Name
Position
J. Scott Wolchko
President, Chief Executive Officer and Director
John Mendlein
Vice Chairman of the Board
William H. Rastetter
Chairman of the Board
Amir Nashat
Director
Mark J. Enyedy
Director
Robert S. Epstein
Director
Timothy P. Coughlin
Director

Shareholders

Name
Position
J. Scott Wolchko
President, Chief Executive Officer and Director
Chris M. Storgard
Chief Medical Officer
Cindy R. Tahl
General Counsel and Corporate Secretary
Daniel D. Shoemaker
Chief Scientific Officer
Stewart Abbot
Chief Development Officer